Pipeline
The Science
About us
Investors
News

Hit enter to search or ESC to close

Prana – ANA Abstract Submission NLP

October 17, 2016 Kerry Rowe

final-ana-abstract-submission-nlp-4-8-16

Post navigation

New data from Reach2HD trial presented at American Neurological Association Annual Meeting

Related Posts

Prana Provides Clinical Trials Update

July 17, 2013

World leader in movement disorders Professor Ira Shoulson joins Prana board

May 13, 2014

Prana drug treatment PBT2 named one of Top Neuroscience Projects to Watch

September 4, 2013

Recent Posts

Alterity Therapeutics meeting with US FDA provides development pathway for ATH434
Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology
Alterity receives a $4.8 million R&D Tax Incentive Refund
European Commission approves Orphan Designation for Alterity’s lead drug candidate
Chairman’s Address to Shareholders 2019 Annual General Meeting

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News
Contact us

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065